Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APN01 (rhACE2) for COVID-19
NCT04335136Phase 2Completed
- Sponsor
- APEIRON Biologics AG
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Peptides, Replacement Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of alunacedase alfa in coronavirus disease 2019 (COVID-19), sponsored by APEIRON Biologics AG. Started Apr 2020; status: completed.
02
Drugs
alunacedase alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04335136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335136.